成人组蛋白修饰高级别胶质瘤放疗后的体积反应与失败模式
本研究纳入2009至2021年诊治的16-50岁组蛋白突变胶质瘤患者,收集临床、影像与病理资料,于诊断时、放疗前、放疗后第1、3、5个月及复发时评估肿瘤体积。538例IDH1/2野生型高级别胶质瘤中18例(15%)存在组蛋白改变,H3K27M突变者放疗后体积反应好但柔脑膜和室管膜下播散倾向高,H3G34R突变者早期体积反应较差且倾向远处脑内失败。
要点
- 538例IDH1/2野生型高级别胶质瘤中18例(15%)有组蛋白改变,H3K27M突变11例、H3G34R突变7例。
- H3K27M突变者放疗后3个月T2F体积缩小>50%见于7例(64%),H3G34R突变者仅1例(14%)。
- H3K27M突变者复发以局部为主(4/9,44%),死亡前柔脑膜播散4/8(50%)、室管膜下播散4/8(50%)。
核心结论
- H3K27M突变胶质瘤对放疗高度敏感,但随后柔脑膜和室管膜下播散倾向高。
- H3G34R突变肿瘤早期体积反应较差,且倾向远处脑内失败。
研究设计与样本
- 回顾性研究,纳入2009至2021年诊治的16-50岁组蛋白突变胶质瘤患者,收集临床、影像和病理特征。
- 在诊断时、放疗前、放疗后第1、3、5个月及复发时通过MRI评估肿瘤体积。
主要发现
- 538例IDH1/2野生型高级别胶质瘤中18例(15%)存在组蛋白改变,其中H3K27M突变11例、H3G34R突变7例。
- 诊断时中位年龄20岁(范围17-48岁),中位总生存期20个月(95%CI 14-29个月)。
- H3K27M和H3G34R突变肿瘤诊断时T2F浸润广泛,中位累及4个神经解剖亚区。
- 放疗前H3K27M突变者T1gd中位体积0.5cm3(IQR 0-1.7cm3)、T2F中位体积11.9cm3(IQR 7.5-29.6cm3);H3G34R突变者T1gd中位体积0.9cm3(IQR 0-8.4cm3)、T2F中位体积43.8cm3(IQR 25.2-86.6cm3)。
- 调强放疗后3个月T2F体积缩小>50%见于H3K27M突变者7例(64%)、H3G34R突变者1例(14%)。
关键数值与推荐
- 14例复发,H3K27M突变者局部-only、 distant-only和两者均有分别为4例(44%)、3例(33%)、2例(22%);H3G34R突变者分别为1例(20%)、2例(40%)、2例(40%)。
- 死亡前末次扫描,H3K27M突变者柔脑膜播散4/8(50%)、室管膜下播散4/8(50%);H3G34R突变者柔脑膜播散1/5(20%)、室管膜下播散0/5。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: H3K27M- and H3G34R-mutant gliomas are recently-classified subgroups of high-grade gliomas (HGGs) affecting younger adults. This study aimed to describe patterns of infiltration and failure, and the volumetric response of these tumours to radiotherapy. METHODS: Patients with histone-mutant gliomas aged 16-50 years, managed from 2009 to 2021 were identified and clinical, radiological and histopathological characteristics collected. Tumour volume was assessed on MRI at diagnosis, pre-radiotherapy, month + 1, + 3 and + 5 post-radiation and at relapse. RESULTS: Of 538 IDH1/2 wild-type HGGs, 18(15%) had a histone alteration. Eleven were H3K27M- and 7 H3G34R-mutant respectively. Median age at diagnosis was 20 years (range17-48 years). Median overall survival was 20 months (95%CI 14-29 months). Both H3K27M- and H3G34R-mutant tumours exhibited extensive T2F infiltration involving a median of 4 neuroanatomical subsites at diagnosis. Median volume of disease pre-radiotherapy on T1gd and T2F respectively was 0.5cm3 (IQR:0-1.7cm3) and 11.9 cm3 (IQR:7.5-29.6cm3) for H3K27M and 0.9cm3 (IQR:0-8.4cm3) and 43.8cm3 (IQR:25.2-86.6 cm3) for H3G34R tumours. T2F volume reduction > 50% was observed 3-months post-IMRT in 7(64%) patients with H3K27M and 1(14%) with H3G34R tumours. Fourteen patients had relapsed. Relapse was local-only, distant-only and both in 4(44%), 3(33%) and 2(22%) H3K27M-mutant and 1(20%), 2(40%), and 2(40%) H3G34R-mutant tumours. On last scan before death, leptomeningeal spread was present in 4/8(50%) and 1/5(20%) and subependymal spread in 4/8 (50%) and 0/5 H3K27M- and G34R-mutant cases respectively. CONCLUSION: H3K27M-mutant gliomas are highly responsive to radiotherapy but exhibit high propensity for subsequent leptomeningeal and subependymal spread. H3G34R-mutant tumours exhibit lesser early volumetric response to radiotherapy and propensity for distant in-brain failure.
引用
- Knight A, Horsley P, Yuile A, et al. Volumetric response and pattern of failure of histone altered high grade glioma in adults following management with radiation therapy. J Neurooncol. 2023. PMID: 37184742. doi:10.1007/s11060-023-04332-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。